NorgesInvestor
NorgesInvestor is an asset management group established in 1996, headquartered in Oslo, Norway, with an additional office in Stockholm, Sweden. The firm specializes in private equity, focusing on mid-market investments in Nordic companies across various sectors, including telecommunications, information technology, retail, alternative energy, oil services, technology, and manufacturing. NorgesInvestor engages in active ownership through its private equity funds and also offers discretionary wealth management and investments in listed securities. Additionally, the firm manages a buyout fund that targets consumer durables and manufacturing sectors in Northern Europe. With a solid financial foundation, NorgesInvestor operates independently and is privately owned.
Algeta ASA is an oncology company based in Oslo, Norway, dedicated to developing targeted therapies for cancer patients using its innovative alpha-pharmaceutical platform. The company's lead product, radium-223 dichloride, has successfully completed Phase III clinical trials for treating castration-resistant prostate cancer with bone metastases. Additionally, Algeta is advancing the development of thorium-227 conjugates, which involve linking the alpha-emitter to tumor-targeting molecules, currently in the preclinical phase. Algeta has established a collaboration with Bayer Pharma AG for the global development and commercialization of radium-223. Founded in 1997, the company originally operated under the name Anticancer Therapeutic Inventions AS before rebranding as Algeta ASA in 2003.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.